BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17631559)

  • 21. MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of
    Gruber L; Jiménez-Franco LD; Decristoforo C; Uprimny C; Glatting G; Hohenberger P; Schoenberg SO; Reindl W; Orlandi F; Mariani M; Jaschke W; Virgolini I
    J Nucl Med; 2020 Dec; 61(12):1749-1755. PubMed ID: 32332143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
    Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
    J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis.
    Nishiyama Y; Yamamoto Y; Fukunaga K; Takinami H; Iwado Y; Satoh K; Ohkawa M
    J Nucl Med; 2006 Oct; 47(10):1571-6. PubMed ID: 17015889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
    AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.
    Guo J; Guo N; Lang L; Kiesewetter DO; Xie Q; Li Q; Eden HS; Niu G; Chen X
    J Nucl Med; 2014 Jan; 55(1):154-60. PubMed ID: 24232871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors.
    Kamiyama Y; Aihara R; Nakabayashi T; Mochiki E; Asao T; Kuwano H; Oriuchi N; Endo K
    World J Surg; 2005 Nov; 29(11):1429-35. PubMed ID: 16222452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
    J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetic analysis of experimental rabbit tumour and inflammation model with 18F-FDG PET/CT.
    Liu P; Huang G; Dong S; Wan L
    Nuklearmedizin; 2009; 48(4):153-8. PubMed ID: 19384450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
    Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
    J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis.
    Dimitrakopoulou-Strauss A; Strauss LG; Burger C
    J Nucl Med; 2001 Feb; 42(2):248-56. PubMed ID: 11216523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG kinetics and gene expression in giant cell tumors.
    Strauss LG; Dimitrakopoulou-Strauss A; Koczan D; Bernd L; Haberkorn U; Ewerbeck V; Thiesen HJ
    J Nucl Med; 2004 Sep; 45(9):1528-35. PubMed ID: 15347720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions.
    Dimitrakopoulou-Strauss A; Strauss LG; Heichel T; Wu H; Burger C; Bernd L; Ewerbeck V
    J Nucl Med; 2002 Apr; 43(4):510-8. PubMed ID: 11937595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET.
    Fukunaga T; Okazumi S; Koide Y; Isono K; Imazeki K
    J Nucl Med; 1998 Jun; 39(6):1002-7. PubMed ID: 9627333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.